Tuesday, October 20, 2026 from 10:15 a.m. to 11:45 a.m. MDT at Salt Palace Convention Center - Ballroom F
This session is being recorded.
Learn MoreAvailable for 1.50 hours of CPE creditActivity Number: 0217-9999-26-120-L02-PActivity Type: An Application-Based ActivityMedication therapy options for PrEP and PEP have evolved over time, and pharmacist involvement in the management of these patients has increased. The purpose of this presentation is to educate clinical pharmacists on updates related to PrEP and PEP services. Pharmacists will learn how to identify patients at increased risk of HIV, how to conduct a sexual health history, and how to perform HIV screening and medication counseling utilizing a status-neutral approach. Pharmacists will also gain insight into patient specific co-morbid conditions that may impact therapy selection for PrEP and PEP.
This activity is approved for Board Certified Ambulatory Care Pharmacist (BCACP) and Board Certified Geriatric Pharmacist (BCGP) recertification credit.
The BCACP and BCGP Clinical Sessions are part of the professional development program for the recertification of board-certified Ambulatory Care or Geriatric pharmacists by the Board of Pharmacy Specialties and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP). In order to earn the BCACP, BCGP recertification credit, participants must attend the session, claim the continuing pharmacy education credit, and pass the associated posttest. Access to the Clinical Sessions posttests will be available on December 16, 2026, at www.accp.com/myaccount to anyone who has purchased access to the BCACP/BCGP posttests. For participants who have not purchased access to the posttests, access can be purchased until 12:00 p.m. on Tuesday, October 20, at the ACCP Registration Desk. The deadline to submit posttests for these sessions will be December 14, 2027.
Learning Objectives1. Assess criteria that may place a patient at high risk of HIV infection.
2. Utilize patient interview skills to conduct a sexual health history and identify HIV risk behaviors.
3. Evaluate patient specific factors that may impact PrEP/PEP therapy selection.
4. Develop a treatment plan for a patient starting PrEP or PEP
5. Apply medication therapy recommendations from the most recent CDC PEP and PrEP guidelines.
 | | Speaker: | Drew L. Armstrong, Pharm.D., FASHP, BCACP, AAHIVP, BC-ADM | | Manager, Ambulatory Clinical Pharmacy
PGY2 Ambulatory Care Residency Program Director
Regional One Health | Memphis, TN
Assistant Professor, UTHSC College of Pharmacy | | View Biography |
|
 | | Speaker: | Spencer H. Durham, Pharm.D., FCCP, BCPS | | Associate Clinical Professor, Pharmacy Practice
Auburn University Harrison College of Pharmacy
Auburn, Alabama | | View Biography |
|